Select Page

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia

Apr 30, 2021

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia

©2020 TIO Bioventures
Terms of Use / Legal Disclaimer
Design by D&CO
New York Office
41 Madison Avenue, 25th Floor
New York, New York, USA, 10010